Recruiting studies: Anaplastic Lymphoma Kinase Alk Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06234579 A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 · 16 location(s) · Astellas Pharma Global Development, Inc. · NCT07140016 Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
NA · 46 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT05122806 Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Phase N/A · 1 location(s) · Sichuan Cancer Hospital and Research Institute · NCT06361589 DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Canc
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770037 Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Phase 3 · 157 location(s) · Nuvalent Inc. · NCT06765109 Alectinib Pharmacokinetic in Patients With NSCLC
Phase 1/Phase 2 · 1 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT05713006 A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (AL
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07001384 A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT05498064 Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Phase 3 · 1 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT05341583 A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small
Phase 2 · 9 location(s) · Centro di Riferimento Oncologico - Aviano · NCT06378892

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.